TWD 16.9
(0.0%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | 178.11 Million TWD | 12.52% |
2022 | 158.29 Million TWD | -67.7% |
2021 | 490.08 Million TWD | 63.7% |
2020 | 299.38 Million TWD | 7.38% |
2019 | 278.81 Million TWD | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q1 | -50.6 Million TWD | -128.41% |
2024 Q2 | -50.6 Million TWD | 6.41% |
2023 Q3 | 170.88 Million TWD | 31.54% |
2023 FY | 178.11 Million TWD | 12.52% |
2023 Q1 | 122.15 Million TWD | -22.83% |
2023 Q2 | 129.9 Million TWD | 6.34% |
2023 Q4 | 178.11 Million TWD | 4.23% |
2022 Q4 | 158.29 Million TWD | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
GeneFerm Biotechnology Co., Ltd. | 31.92 Million TWD | -457.893% |
Easywell Biomedicals, Inc. | 123.43 Million TWD | -44.295% |
TTY Biopharm Company Limited | -705.97 Million TWD | 125.229% |
Synmosa Biopharma Corporation | 1.52 Billion TWD | 88.292% |
Orient EuroPharma Co., Ltd. | 3.1 Billion TWD | 94.266% |
Center Laboratories, Inc. | 3.91 Billion TWD | 95.455% |
Tien Liang BioTech Co., Ltd. | -57.55 Million TWD | 409.46% |
Orient Pharma Co., Ltd. | 633.6 Million TWD | 71.889% |
InnoPharmax Inc. | -17.85 Million TWD | 1097.385% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | -926.77 Million TWD | 119.219% |
Excelsior Biopharma Inc. | -212.51 Million TWD | 183.813% |
DV Biomed Co., Ltd. | 160.7 Million TWD | -10.836% |
Foresee Pharmaceuticals Co., Ltd. | -781.42 Million TWD | 122.793% |
Handa Pharmaceuticals, Inc. | -653.8 Million TWD | 127.242% |
UniPharma Co., Ltd. | -68.36 Million TWD | 360.525% |
Anxo Pharmaceutical Co., Ltd. | 492.4 Million TWD | 63.828% |
Alar Pharmaceuticals Inc. | -738.05 Million TWD | 124.133% |
Winston Medical Supply Co., Ltd. | -191.81 Million TWD | 192.859% |
Mercury Biopharmaceutical Corporation | -1.94 Million TWD | 9257.481% |
Bioray Biotech Co., Ltd | -27.23 Million TWD | 754.058% |
TSH Biopharm Corporation Limited | -568.74 Million TWD | 131.317% |